跳至主要内容
临床试验/NCT04961580
NCT04961580招募中不适用

Pharmacokinetics and Pharmacodynamics of Ceftazidime Avitbatan Sodium in Children With Severe Infection

Children's Hospital of Fudan University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
30
试验地点
1
主要终点
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter

研究概览

简要总结

Ceftazidime avitbatan sodium is a broad-spectrum antibiotic with an antimicrobial spectrum covering resistant gram-negative bacteria. Its use in pediatric intensive care for severe infections is not unusual. Pathophysiological changes in severe sepsis can lead to significant changes in pharmacokinetics and pharmacodynamics during continuous renal replacement therapy.This research aims to study change of pharmacokinetic and pharmacodynamic in severe infection children with extracorporeal life support, thus improve the treatment of severe sepsis and sepsis shock.

详细描述

This study is an observational clinical study. Subjects were recruited from children with severe infection receiving ceftazidime avitbatan sodium under routine clinical diagnosis and treatment routine. There is no control, no double-blind randomized design, and the normal treatment schedule of patients was not interfered with, and the disease risk of patients was not increased.All subjects had received at least 5 doses of ceftazidime avitbatan Sodium before enrollment.

Blood sampling time points of ceftazidime avitbatan sodium are listed as follow:

Before administration (0 min); 5,30 min,1 h,2 h,4 h and 8 h after administration, if blood purification is received, one blood sample will be collected before and after the filter at the same time point.

The concentration of ceftazidime avitbatan sodium in whole blood will be analyzed at Huashan Hospital of Fudan University.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
3 Months 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Children who are admitted in the pediatric intensive care unit receiving ceftazidime avitbatan sodium

排除标准

  • No Informed Consent signed
  • Participate in other clinical trials

研究组 & 干预措施

Ceftazidime avitbatan sodiumt group

Children treated with ceftazidime avitbatan sodium in the pediatric intensive care unit will be enrolled in this group. Blood sample will be retained at various time intervals for pharmacokinetics.

干预措施: Ceftazidime Avitbatan Sodium (Drug)

结局指标

主要结局

Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter

时间窗: Day 1-5

Time to reach the maximum plasma concentration (Tmax) after administrations of a single dose and multiple doses of the study drug

次要结局

  • Terminal Phase Elimination Half-life (T1/2) Pharmacokinetic Parameter(Day 1-5)
  • AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Pharmacokinetic Parameter(Day 1-5)
  • AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Pharmacokinetic Parameter(Day1-5)
  • Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter(Day1-5)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验